The formation of new blood vessels, called angiogenesis, is an essential pathophysiological
process in which several families of regulators have been implicated. Among these, vascular …

Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …

Faricimab (faricimab-svoa; Vabysmo™) is a bispecific antibody that binds to and inhibits
both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2). Administered …

Importance Age-related macular degeneration (AMD) affects approximately 20 million
people in the US and 196 million people worldwide. AMD is a leading cause of severe …

Although pivotal aflibercept trials used a fixed-dose regimen, 12 most retinal specialists
favour a variable-dose method, 9 suggesting that trials reflecting the real-world use of …

Abstract Background/Objective Investigate real-world patients receiving faricimab for the
treatment of neovascular age-related macular degeneration (nAMD). Subjects/Methods …

Neovascular age-related macular degeneration (nAMD) is a major cause of visual
impairment and blindness. Anti-vascular endothelial growth factor (VEGF) agents, such as …

In this 14th installment of the annual Antibodies to Watch article series, we discuss key
events in commercial monoclonal antibody therapeutics development that occurred in 2022 …

Age-related macular degeneration AMD is one of the leading causes of blindness in the
elderly population. An advanced form of AMD known as neovascular AMD (nAMD) is …

Age-related macular degeneration (AMD) is the leading cause of visual impairment in the
aging population with a limited understanding of its pathogenesis and the number of …